Under specific pathological conditions, downregulation of JAZF1 expression is observed, and this reduction in JAZF1 levels has been implicated in the pathogenesis of metabolic disorders such as obesity, diabetes, and hepatic steatosis [21–24]. Here, JAZF1 is linked to fatty liver disease.